Following our name change to become @Immutep last year, we will be shutting down this Twitter account soon. Stay up to date by following @Immutep!immutep.com AustraliaJoined April 2011
Join us for a Key Opinion Leader call this week!
Immutep Ltd. will host a key opinion leader (KOL) call on novel immuno-oncology therapy (eftilagimod alpha) in the treatment of metastatic breast cancer and other settings.
Call will take place on... immutep.com
James Dunn from nabtrade recently looked at Immutep Ltd. in his article 'Four ASX cancer stocks under the microscope', highlighting the potential for our lead product candidate, efti, and the opportunity stemming from our AIPAC phase II clinical trial:... bit.ly/2YTQLFn
Immutep Ltd. has been granted another US patent for efti.
This new patent provides intellectual property protection for Immutep’s method of treating cancer by the administration of a chemotherapy agent, and a plurality of doses of efti.... bit.ly/2Yh1Sbd
Join us for a global webcast to discuss Immutep Ltd.'s recent preclinical results relating to IMP761 in #autoimmunedisease on:
Tuesday, March 26, 2019, 7:45 am Australian Eastern Daylight Time,
or
Monday, March 25, 2019, 4:45 pm US Eastern Daylight... bit.ly/2Tfjhxd
Marc Voigt spoke with Finance News Network
about Immutep Ltd.'s recent progress and exciting news flow ahead.
Even with a busy week of data behind us, from TACTI-mel and IMP761, Immutep still has a great deal of clinical data that it will report... bit.ly/2TBVXig
Late last week, Immutep Ltd. received a A$872,351 cash rebate from the Australian Federal Government’s R&D tax incentive program.
The rebate is for its eligible R&D activities conducted in the 2018 fiscal year and is mainly related to the Company’s... bit.ly/2NPHl8t
Immutep Ltd. today announced positive results from its preclinical study of IMP761, a novel LAG3 agonist antibody being developed for the treatment of #AutoimmuneDiseases.
This new study showed that IMP761 decreases inflammatory T cell infiltration... bit.ly/2tSbZoR
Immutep Ltd. today announced positive, more mature data from its ongoing TACTI-mel phase I clinical study of the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”). The data will be presented at the World Immunotherapy Congress... immutep.com
Immutep Ltd. has published its half year report for the period ended 31 December 2018, on Immutep Ltd and its subsidiaries. Click the link below to the Half Year Report bit.ly/2Xvdxmn
Immutep Ltd. has published its half year report for the period ended 31 December 2018, on Immutep Ltd and its subsidiaries.
Click the link below to the Half Year Report bit.ly/2Xvdxmn
Immutep Ltd. will be presenting updated clinical data from the Phase I TACTI-mel trial in metastatic melanoma for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) at World Immunotherapy Congress USA 2019 being held from 3-5 March 2019.... bit.ly/2GK6hxz
Our new collaboration with CYTLIMIC has been covered by online publication Stockhead.
"Cancer biotech Immutep’s flagship drug is to be used in conjunction with a cancer peptide vaccine discovered by artificial intelligence in new Japanese clinical... bit.ly/2TAsZuz
Immutep Ltd.'s recent news, including two new EU patents and further TACTI-mel data, has been highlighted in online news publication, Small Caps. bit.ly/2E8Kpe5
Immutep Ltd. CEO Marc Voigt spoke with FNN about the Company's recent progress, its new partnerships and what's coming up next in terms of meaningful clinical work.
#Immunotherapyyoutu.be/S01-fzPAYZ8
Immutep Ltd.'s partner CYTLIMIC recently presented the results of its YNP001 study at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting.
The YNP001 study is a First-in-Human study of the cancer peptide vaccine... cytlimic.com/news/20181012_…
Immutep Ltd. today announced new positive interim data from its ongoing TACTI-mel Phase I clinical trial, presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., U.S.
Dr. Frédéric Triebel, Immutep’s... bit.ly/2PVe0Nu
Immutep Ltd. CEO Marc Voigt recently spoke with Your Money's Ingrid Willinge about the Company's growing trial and partnership momentum. bit.ly/2ARH2oQ
Immutep Ltd. today provided an operational update on the Company’s ongoing clinical and preclinical development of eftilagimod alpha (“efti” or “IMP321”) and IMP761, respectively, as well as the Company’s partnered clinical programs.
Highlights... bit.ly/2JtzjAe
This Washington Post video (via the article) includes a good explanation of how Nobel Laureates and cancer researchers James P. Allison and Tasuku Honjo revolutionised cancer treatment by determining how to disengage the “brakes” that prevent the... wapo.st/2CB6kZN
77 Followers 1K FollowingPRIMER Y ÚNICO LABORATORIO PRIVADO DE REFERENCIA DESIGNADO POR LA UE (EURL)
Primer laboratorio clínico privado en España acreditado por ENAC
59 Followers 316 FollowingA biomedical startup founded in 2017. Our mission is to transform the study of human biology. Current project with @Sydney_uni: an advanced 4D bioreactor system
281 Followers 1K FollowingStudio digital de solutions et de promotion sur-mesure pour les entrepreneurs et les entreprises
#transformationdigitale #applications #PME #digitale #startup
371 Followers 2K FollowingBiotechnologist✨, iGEMer @iGEM_Ecuador (Playing with bacteria to make the world a better place🦠), Synbio ESPE Club Co-Founder, Research Technician at FEPIS Lab
144 Followers 724 FollowingBiomedical Research is open access journal that specifies and describes the development activities conducted in the field of Medical research.
38 Followers 1K FollowingEmerging Technology Evaluation in field of #Cancer #DrugDevelopment Check @OmicsX @CROLinker @Biostartups and @IdentifyEvents for updates in #Drugdiscovery.
400 Followers 2K FollowingA platform to converse concerning the current developments, new approaches and future approaches in the field of #cancer #science & #therapy | March 09-10 2020
125 Followers 920 FollowingA frontier of SciTechnol, bent upon publishing quality articles related to medical biotechnology, latest reserach in pharmacogenomics,stem cells,neurocience,etc
385 Followers 341 FollowingUltraSolutions is one of the leading ultrasound equipment dealers in the ultrasound industry. Providing your staff and budget with the right solution every time
63 Followers 639 FollowingRetired Maths teacher and chairperson (volunteer from 1996) of Association P.A.V.E.L., a NGO for children, young people and patients with cancer from Romania.
104 Followers 382 FollowingThis page aims to provide the interested audience with information on cancer and keep them up-to-date on recent scientific discoveries. By Mayassa Bou-Dargham
149 Followers 857 FollowingSenior Web Developer with a passion for art, design, music & creative thinking. (currently not for hire, but am very interested in networking.)
2K Followers 5K FollowingThe drug development accelerator-create more drugs with better profile in clinical trials- we valorize your pipeline! #cardiomyocytes #stemcells #iPS #biotech
322 Followers 1K Following#intergarting and #innovating the #ideas of #cancer #therapeutics
#international #conference on #cancerbiology and #therapeutics #toronto #canada #Oct2324
28 Followers 365 FollowingFlorida based hearing and balance service and calibration company. Providing quality customer service keeping the customer first.
264 Followers 2K FollowingWith time running out, a lone warrior travels back in time to prevent a future genocide.
Warped: A proof-of-concept sci-fi/thriller short for the LAFP 2017
509 Followers 736 FollowingChanging the Cancer Conversation by supporting parents & medical professionals 🎗#childhoodcancer 🎗 Founded by a mom of a #Miraclekid
86 Followers 140 FollowingBorn in So.CA, 1958, Cancer Survivor, Artist & Psychologist. Love Jesus, Billy, The Kids--enjoy Scuba, Hiking, Nature, Art & tea on our Lanai!
695 Followers 352 FollowingPublisher and Editor-in-Chief, Elk Lake Publishing, Inc., and book reviewer and blogger about positive books @ https://t.co/gIjHrzvvE5
260 Followers 875 FollowingAn addict to science.Voracious reader.Very frank,honest,smart,sassy & an innovative budding scientist in the field of Biotechnology (Cancer Biology) from India.
58 Followers 173 FollowingCaramel brown mother of 2 beauitful kids jr. & mookie. Brown eyez & hair ht57/wt175 out goin,funny,smart & I’m a CANCER ♋️ wit alot of talent. LOl
226 Followers 2K FollowingMedical Laboratory Scientist Continuous cancer survivor. Grad student….Graduated! Life is change and change is good. IG:Abraxas13
40 Followers 74 Following5'2 Long hair don't care I aint never been a mix breed, im on a diet but im doin doughnuts in the 6-speed #TeamNative #TEAMBOUTITBOUTIT'
64 Followers 33 FollowingHaving a son who has been diagnosed with Autism. A mother who passsed away of Pancreatic Cancer in 2008. It is my duty to spread awareness~~
605 Followers 1K FollowingFounded by a 3x cancer survivor/Woman of God/providing a 1-on-1 support system to others faced with cancer challenges. https://t.co/QSFFYwjqza
63 Followers 639 FollowingRetired Maths teacher and chairperson (volunteer from 1996) of Association P.A.V.E.L., a NGO for children, young people and patients with cancer from Romania.
830 Followers 2K FollowingPublic Health, Grant Writer, Breast CA Survivor. Committed to increasing access to healthcare for ALL. Specialties: Latino, Native American, low-income & rural.
520 Followers 477 FollowingDocumentary film marketing and distribution ideas. Tweets are by @IlesParker who is currently Partner and CMO of @SpeakingPhoto.
132 Followers 171 FollowingWriter of words / taker of pictures / designer of pages / listener of music / viewer of movies / watcher of television / father of daughter
1K Followers 1K FollowingPublicist for my own firm in Beverly Hills, CA. Now accepting new clientele from Athletes to Artists. Inquire today to see what we can do for you!
202 Followers 334 Followingİmaj ve Basın Danışmanı//Eski Gazeteci//Kemo Şapkası Fikir sahibi//Romans Yayınları Yazarı// 1 Kişilik Dev Kadro// Mevlana Hayranı💜